Dr. Salituro, founder of Salituro MedChem Solutions, LLC, has been a scientific leader in pharmaceutical industry since 1986 and has successfully driven drug discovery programs across multiple therapeutic areas. His work has resulted in 20 small molecule clinical candidates, including Zuranolone (SAGE-217), SAGE-718, SAGE-324, SAGE-904, Neflamopimod, Decernotinib, Pimodivir, and 4 marketed drugs, Zulresso®, IDHIFA® ,TIBSOVO® and Pyrukynd®.
Most recently, he held the position of Vice President of Chemistry at Sage Therapeutics, from 2012 through 2020. Prior to Sage, he held leadership positions at Agios Pharmaceuticals, Wyeth Research and Vertex Pharmaceuticals after initially joining Merrell Dow Pharmaceuticals in 1986. Dr. Salituro’s research has led to over 60 scientific publications and over 80 issued US Patents. Additionally, he has been active within the Gordon Research Conferences, serving as Chairman of the prestigious GRC on Medicinal Chemistry in 2011.
Since September of 2014, he has been serving on the Board of Directors for the Epilepsy Foundation of New England (EFNE). He is also the co-founder of Joseph’s HOPE Scholarship Fund, and more recently the Joseph’s HOPE Emergency Fund, both of which are within the EFNE umbrella.
Dr. Salituro received his B.S. Degree in Life Sciences from the University of Wisconsin-Parkside in 1980 and his Ph.D. in Medicinal Chemistry from the University of Wisconsin-Madison in 1984; he additionally held a postdoctoral position at University of Illinois-Champaign Urbana from 1984-1986.